In a dengue patient with suspected secondary hemophagocytic lymphohistiocytosis, when should a bone‑marrow biopsy be performed and what precautions are required?

Bone Marrow Biopsy Timing and Precautions in Dengue-Associated HLH

Perform bone marrow biopsy when dengue patients exhibit persistent or recurrent fever beyond 7 days after onset, along with worsening or persistent cytopenias (particularly thrombocytopenia, neutropenia, anemia) that continue despite resolution of the critical phase, especially when accompanied by hepatosplenomegaly and markedly elevated ferritin (>3000 ng/mL). 1, 2

When to Suspect and Pursue Bone Marrow Evaluation

The key clinical trigger is persistent fever after the expected dengue timeline. Normal dengue follows a predictable course with fever resolution by day 5-7. Consider HLH and pursue bone marrow biopsy when you observe:

Red Flag Clinical Features:

• Fever persisting >7 days or recurring after initial defervescence 1, 2
• Progressive cytopenias despite passing the critical phase (days 3-7) 1
• Hepatosplenomegaly developing or worsening 1, 3
• Anemia without evidence of massive bleeding or intravascular hemolysis 2
• Failure to respond to supportive dengue management 4, 3

Laboratory Thresholds Prompting Evaluation:

• Serum ferritin >3000 ng/mL 1
• Triglycerides >265 mg/dL 1
• Soluble IL-2 receptor markedly elevated 4
• Persistent thrombocytopenia (mean ~58,000/μL in HLH cases) 5
• Elevated ESR and prolonged PT/INR 5

Diagnostic Approach

Bone marrow biopsy confirms the diagnosis of HLH and is essential when clinical suspicion is high 5, 6. The biopsy will demonstrate increased hemophagocytic activity—macrophages actively engulfing blood cells 1, 4.

Apply the HLH-2004 diagnostic criteria (need ≥5 of 8 criteria) 7, 1, 2:

1. Fever
2. Splenomegaly
3. Cytopenias (≥2 cell lines)
4. Hypertriglyceridemia and/or hypofibrinogenemia
5. Hemophagocytosis in bone marrow
6. Low/absent NK cell activity
7. Ferritin ≥500 ng/mL
8. Elevated soluble CD25 (IL-2 receptor)

Critical Precautions for Bone Marrow Biopsy

Thrombocytopenia Management:

The primary concern is severe thrombocytopenia, which is universal in dengue-HLH cases. Before proceeding:

• Platelet transfusion should be administered if counts are critically low (typically <20,000-30,000/μL for procedures)
• Assess coagulation parameters (PT/INR, aPTT) as these are frequently prolonged 5
• Correct coagulopathy with fresh frozen plasma if INR is significantly elevated
• Apply prolonged local pressure post-procedure given the bleeding risk

Timing Considerations:

• Do not delay if clinical deterioration is rapid—HLH carries high mortality if untreated 5, 6, 1
• The procedure can be performed during the critical phase if HLH is strongly suspected, as early diagnosis enables life-saving treatment
• Balance procedural risk against the mortality risk of untreated HLH (which is substantial)

Technical Approach:

• Use the posterior iliac crest (standard site with good compression capability)
• Ensure experienced operator given the coagulopathy
• Have transfusion support readily available
• Monitor biopsy site closely for bleeding complications

Treatment Implications

Recognition matters because treatment differs fundamentally from dengue management alone. Once HLH is confirmed:

• High-dose corticosteroids are first-line: dexamethasone 10 mg/m²/day for 3-4 days, then taper over 8 weeks 1, 4, 2
• Intravenous immunoglobulin (IVIG) showed 100% recovery in one pediatric series of 19 patients 5
• Early steroid therapy (even half-dose pulse therapy) can be dramatically effective 4
• Favorable outcomes are achievable with steroid therapy alone in dengue-associated HLH 2

Common Pitfalls to Avoid

1. Assuming all cytopenias are "just dengue"—if fever persists beyond day 7 or cytopenias worsen after the critical phase, think HLH 1, 2

2. Waiting too long for biopsy due to thrombocytopenia concerns—untreated HLH has higher mortality than procedural bleeding risk when properly managed 5, 6

3. Missing the diagnosis entirely—dengue-associated HLH is rare but disproportionately affects severe cases with significant mortality impact 2

4. Failing to check ferritin and triglycerides—these simple tests can raise suspicion before committing to bone marrow biopsy 1

The evidence consistently shows that early recognition through bone marrow confirmation enables prompt immunosuppressive therapy, which is associated with good outcomes in dengue-associated HLH 1, 4, 2. The key is maintaining high clinical suspicion when the dengue course deviates from expected patterns.